Ovarian protection during adjuvant chemotherapy [4]

New England Journal of Medicine

Volumn 372, Issue 23, 2015, Pages 2268-2269

  Oktay, Kutluk ^a   Rodriguez Wallberg, Kenny ^b   Munster, Pamela ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN DERIVATIVE; INHIBIN B; ANTINEOPLASTIC AGENT; GONADORELIN; GOSERELIN;

AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CRYOPRESERVATION; DRUG EFFICACY; DRUG SAFETY; FEMALE FERTILITY; FERTILITY PRESERVATION; HUMAN; LETTER; OVARIAN RESERVE; OVARY FOLLICLE; OVARY INSUFFICIENCY; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGONISTS; BREAST NEOPLASMS; FEMALE; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84930526398     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1504241     Document Type: Letter

References (4)

1. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-41.
2. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-8.
3. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013;121:78-86.
4. Oktay K, Sönmezer M. Gonadotropin-releasing hormone analogs in fertility preservation-lack of biological basis? Nat Clin Pract Endocrinol Metab 2008;4:488-9.